These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

751 related items for PubMed ID: 18929236

  • 1. Intensity of antiplatelet therapy in patients with acute coronary syndromes and percutaneous coronary intervention: the promise of prasugrel?
    Wiviott SD.
    Cardiol Clin; 2008 Nov; 26(4):629-37. PubMed ID: 18929236
    [Abstract] [Full Text] [Related]

  • 2. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis.
    Antman EM, Wiviott SD, Murphy SA, Voitk J, Hasin Y, Widimsky P, Chandna H, Macias W, McCabe CH, Braunwald E.
    J Am Coll Cardiol; 2008 May 27; 51(21):2028-33. PubMed ID: 18498956
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38).
    Wiviott SD, Antman EM, Gibson CM, Montalescot G, Riesmeyer J, Weerakkody G, Winters KJ, Warmke JW, McCabe CH, Braunwald E, TRITON-TIMI 38 Investigators.
    Am Heart J; 2006 Oct 27; 152(4):627-35. PubMed ID: 16996826
    [Abstract] [Full Text] [Related]

  • 4. Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)-Thrombolysis in Myocardial Infarction (TIMI) 38 substudy.
    Pride YB, Wiviott SD, Buros JL, Zorkun C, Tariq MU, Antman EM, Braunwald E, Gibson CM, TIMI Study Group.
    Am Heart J; 2009 Sep 27; 158(3):e21-6. PubMed ID: 19699846
    [Abstract] [Full Text] [Related]

  • 5. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis.
    O'Donoghue M, Antman EM, Braunwald E, Murphy SA, Steg PG, Finkelstein A, Penny WF, Fridrich V, McCabe CH, Sabatine MS, Wiviott SD.
    J Am Coll Cardiol; 2009 Aug 18; 54(8):678-85. PubMed ID: 19679245
    [Abstract] [Full Text] [Related]

  • 6. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction.
    Morrow DA, Wiviott SD, White HD, Nicolau JC, Bramucci E, Murphy SA, Bonaca MP, Ruff CT, Scirica BM, McCabe CH, Antman EM, Braunwald E.
    Circulation; 2009 Jun 02; 119(21):2758-64. PubMed ID: 19451347
    [Abstract] [Full Text] [Related]

  • 7. Antiplatelet therapy in percutaneous coronary intervention: integration of prasugrel into clinical practice.
    Thomas D, Giugliano RP.
    Crit Pathw Cardiol; 2009 Mar 02; 8(1):12-9. PubMed ID: 19258833
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of prasugrel compared with clopidogrel in patients with acute coronary syndromes: results of TRITON-TIMI 38 trials.
    Mariani M, Mariani G, De Servi S.
    Expert Rev Cardiovasc Ther; 2009 Jan 02; 7(1):17-23. PubMed ID: 19105763
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38.
    Mahoney EM, Wang K, Arnold SV, Proskorovsky I, Wiviott S, Antman E, Braunwald E, Cohen DJ.
    Circulation; 2010 Jan 05; 121(1):71-9. PubMed ID: 20026770
    [Abstract] [Full Text] [Related]

  • 10. The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes.
    Toth PP.
    Postgrad Med; 2009 Jan 05; 121(1):59-72. PubMed ID: 19179814
    [Abstract] [Full Text] [Related]

  • 11. Prasugrel in acute coronary syndrome patients undergoing percutaneous coronary intervention.
    Capranzano P, Ferreiro JL, Angiolillo DJ.
    Expert Rev Cardiovasc Ther; 2009 Apr 05; 7(4):361-9. PubMed ID: 19379060
    [Abstract] [Full Text] [Related]

  • 12. Prasugrel: Clinical development and therapeutic application.
    Guerra DR, Tcheng JE.
    Adv Ther; 2009 Nov 05; 26(11):999-1011. PubMed ID: 20020231
    [Abstract] [Full Text] [Related]

  • 13. Prasugrel: a critical comparison with clopidogrel.
    Reinhart KM, White CM, Baker WL.
    Pharmacotherapy; 2009 Dec 05; 29(12):1441-51. PubMed ID: 19947804
    [Abstract] [Full Text] [Related]

  • 14. Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel.
    Prescrire Int; 2009 Oct 05; 18(103):193-5. PubMed ID: 19877380
    [Abstract] [Full Text] [Related]

  • 15. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial.
    Wiviott SD, Antman EM, Winters KJ, Weerakkody G, Murphy SA, Behounek BD, Carney RJ, Lazzam C, McKay RG, McCabe CH, Braunwald E, JUMBO-TIMI 26 Investigators.
    Circulation; 2005 Jun 28; 111(25):3366-73. PubMed ID: 15967851
    [Abstract] [Full Text] [Related]

  • 16. Clinical profile of prasugrel, a novel thienopyridine.
    Angiolillo DJ, Bates ER, Bass TA.
    Am Heart J; 2008 Aug 28; 156(2 Suppl):S16-22. PubMed ID: 18657682
    [Abstract] [Full Text] [Related]

  • 17. Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist.
    Mousa SA, Jeske WP, Fareed J.
    Clin Appl Thromb Hemost; 2010 Apr 28; 16(2):170-6. PubMed ID: 20299391
    [Abstract] [Full Text] [Related]

  • 18. Prasugrel: newest antiplatelet agent and its emerging role in management of acute coronary syndrome and percutaneous coronary intervention.
    Robinson A, Das K, Koshy SK, Das P.
    Future Cardiol; 2009 May 28; 5(3):237-46. PubMed ID: 19450050
    [Abstract] [Full Text] [Related]

  • 19. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38).
    Kohli P, Udell JA, Murphy SA, Cannon CP, Antman EM, Braunwald E, Wiviott SD.
    J Am Coll Cardiol; 2014 Jan 28; 63(3):225-32. PubMed ID: 24140678
    [Abstract] [Full Text] [Related]

  • 20. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial.
    Wiviott SD, Trenk D, Frelinger AL, O'Donoghue M, Neumann FJ, Michelson AD, Angiolillo DJ, Hod H, Montalescot G, Miller DL, Jakubowski JA, Cairns R, Murphy SA, McCabe CH, Antman EM, Braunwald E, PRINCIPLE-TIMI 44 Investigators.
    Circulation; 2007 Dec 18; 116(25):2923-32. PubMed ID: 18056526
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.